Medication info

Lovaex Tablet 20/160 milligrams

Prescription medicationTabletOralExpired
Ingredient · strength
Rosuvastatin Calcium›20.8mg / 1 tabletValsartan›160mg / 1 tablet
Manufacturer / importer
Teragen Etex Co., Ltd.
Appearance
Brown oval film-coated tablet
Packaging
30 tablets/box [10 tablets/PTPX3]
Approval status
Expired

MFDS item code 202003851 · Approved 2020.05.26

This product's status changed to Expired on 2025.05.26. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of dyslipidemia, hypertension, and heart failure; reduction of cardiovascular risk; inhibition of atherosclerosis progression
Who takes it
Adults · Children
Adult dose
This medicine is for use in adults only. The dosage should be individualized for each patient based on the efficacy and tolerability of the valsartan and rosuvastatin components. ◆ Valsartan 1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended that the medicine be taken at the same time each day (e.g., in the morning). Adults: Regardless of sex or race, the recommended dose is 80 mg orally once daily as valsartan. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. In patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be used concomitantly. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. Older adults (75 years and older): Initiate treatment with 40 mg once daily of this medicine. Patients with renal impairment: Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg once daily of this medicine. Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. Patients with intravascular volume depletion: In patients with intravascular volume depletion (e.g., patients receiving high-dose diuretics whose dose cannot be reduced), initiate treatment with 40 mg once daily of this medicine. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, initiate treatment with 40 mg once daily of this medicine; the dose should not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg orally twice daily as this medicine; the dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction in the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg twice daily as this medicine. Over the following weeks, the dose may be increased, according to the patient's tolerability, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is 10 mL/min or higher. However, do not administer this medicine to patients with creatinine clearance less than 10 mL/min or to patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and should continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased to a maximum of 20 milligrams daily. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40 milligrams dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40 milligrams dose of this medicine is contraindicated in some of these patients. Patients taking valsartan and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.
Child dose
Children and adolescents under 18 years of age: Safety and efficacy have not been established. Children and adolescents under 18 years of age: Safety and efficacy have not been established.

Ingredients

Manufacturer
Teragen Etex Co., Ltd.

Efficacy & effects

Treatment of dyslipidemia, hypertension, and heart failure; reduction of cardiovascular risk; inhibition of atherosclerosis progression

  • Essential hypertension
  • heart failure
  • heart failure intolerant to ACE inhibitors
  • left ventricular failure
  • left ventricular systolic dysfunction
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
View approved original text

This medication is used for patients who require the simultaneous administration of valsartan and rosuvastatin. Valsartan helps reduce essential hypertension, heart failure (especially in patients intolerant to ACE inhibitors), and the risk of death after myocardial infarction. Rosuvastatin is used to control hypercholesterolemia and hyperlipidemia, slowing the progression of atherosclerosis and reducing the risk of cardiovascular diseases and stroke and myocardial infarction. Together, these two medications effectively manage hypertension and cardiovascular risk, improving the overall cardiovascular health of patients.

How to take

Adult dose

This medicine is for use in adults only. The dosage should be individualized for each patient based on the efficacy and tolerability of the valsartan and rosuvastatin components. ◆ Valsartan 1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended that the medicine be taken at the same time each day (e.g., in the morning). Adults: Regardless of sex or race, the recommended dose is 80 mg orally once daily as valsartan. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. In patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be used concomitantly. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. Older adults (75 years and older): Initiate treatment with 40 mg once daily of this medicine. Patients with renal impairment: Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg once daily of this medicine. Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. Patients with intravascular volume depletion: In patients with intravascular volume depletion (e.g., patients receiving high-dose diuretics whose dose cannot be reduced), initiate treatment with 40 mg once daily of this medicine. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, initiate treatment with 40 mg once daily of this medicine; the dose should not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg orally twice daily as this medicine; the dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction in the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg twice daily as this medicine. Over the following weeks, the dose may be increased, according to the patient's tolerability, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is 10 mL/min or higher. However, do not administer this medicine to patients with creatinine clearance less than 10 mL/min or to patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and should continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased to a maximum of 20 milligrams daily. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40 milligrams dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40 milligrams dose of this medicine is contraindicated in some of these patients. Patients taking valsartan and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Child dose

Children and adolescents under 18 years of age: Safety and efficacy have not been established. Children and adolescents under 18 years of age: Safety and efficacy have not been established.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, particularly in the second and third trimesters, so it should be discontinued immediately if pregnancy is confirmed. Women of childbearing potential must use appropriate contraceptive methods before taking this medication, and it should not be taken if pregnant or nursing. This medication should not be administered to patients with severe liver or kidney impairment, muscle diseases, or certain allergic reactions. Caution is especially required when administering this medication to elderly patients or those with high potassium levels or liver dysfunction, and regular liver function or kidney function tests should be performed. This medication may cause muscle pain or weakness and, rarely, severe muscle damage (rhabdomyolysis); if any unusual symptoms occur in the muscles, medical personnel should be notified immediately. Additionally, interactions may occur when used with other medications, so any current medications should be disclosed to medical personnel. Alcohol consumption should be avoided or limited during treatment, and care should be taken when driving or operating machinery as dizziness may occur. In case of overdose, as no specific antidote exists, immediate medical attention should be sought. This medication is not recommended for use in children or adolescents, as safety and efficacy have not been adequately established. This medication should be kept out of reach of children and should not be transferred to other containers.

Side effects

Dyspepsia, nausea, chest discomfort, dizziness, headache, conjunctival hemorrhage, constipation, weakness, chest pain, facial swelling, peripheral edema, nasopharyngitis, urinary tract infection, contusion, elevated serum liver aminotransferase levels, increased serum creatinine phosphokinase, increased serum potassium, elevated gamma-glutamyl transferase, musculoskeletal rigidity, limb pain, sensory loss, anxiety, upper respiratory tract infection, pharyngitis, tonsillitis, spinal canal stenosis, aphasia, oral hemorrhage, vomiting, insulin-dependent diabetes mellitus, diabetes complications, leg fracture, spinal fracture, fracture, skin mass, second-degree atrioventricular block, vestibular neuritis, retinal detachment, unspecified skin tumor-like condition, herpes zoster, intervertebral disc herniation, hemoptysis, sputa disease, bronchitis, sensory abnormalities, hoarseness, gastroesophageal reflux, diverticulitis, gastritis, stomatitis, carpal tunnel syndrome, chills, facial flushing, increased blood sugar, increased triglycerides, elevated blood pressure, hypertension exacerbation, neck/shoulder pain, toe fracture, osteomyelitis, skin infection, unspecified dermatitis, localized skin reaction, palpitations, angina exacerbation, auditory abnormalities, overactive bladder, increased serum creatinine, benign prostatic hyperplasia, laceration, headache, dizziness, viral infection, upper respiratory infection, cough, diarrhea, fatigue, rhinitis, sinusitis, abdominal pain, abdominal pain, joint pain, drowsiness, atrial fibrillation, constipation, thirst, decreased appetite, lethargy, vascular edema, redness, itching, serum sickness, vasculitis, renal function impairment, syncope, nasal bleeding, hepatitis, arrhythmia, interstitial pneumonia, hypoglycemia, shock, loss of consciousness, rhabdomyolysis, agranulocytosis, leukopenia, thrombocytopenia, reduced red blood cell volume, decreased hemoglobin, hypotension, orthostatic dizziness, orthostatic hypotension, renal function impairment, hyperkalemia, blood pressure lowering, angioedema, decreased urine output, progressive hyperazotemia, acute kidney failure, elevated serum creatinine, increased BUN, elevated liver function test values, edema, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, dyspnea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, joint pain, immune-mediated necrotizing myopathy, hematuria, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, liver failure, cognitive impairment, severe muscle weakness, ocular myasthenia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in a container that protects it from light. Additionally, it is best stored at room temperature between 1°C and 30°C. Storing it this way helps maintain the medication's effectiveness for longer.

Appearance and packaging

Appearance

Brown oval film-coated tablet

Package unit

30 tablets/box [10 tablets/PTPX3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.